265 related articles for article (PubMed ID: 29333021)
1. Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Agarwal MB; Bhurani D; Shah C; Sood N; Singhal M; Kamat A; Chezhian S; Mishra S; Nagrale D
Indian J Med Paediatr Oncol; 2017; 38(4):508-515. PubMed ID: 29333021
[TBL] [Abstract][Full Text] [Related]
2. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
7. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
8. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey.
Göçer M; Kurtoğlu E
Blood Res; 2020 Dec; 55(4):206-212. PubMed ID: 33303706
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
11. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
[TBL] [Abstract][Full Text] [Related]
12. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Stephens DM; Huang Y; Ruppert AS; Walker JS; Canfield D; Cempre CB; Fu Q; Baker S; Hu B; Shah H; Vadeboncoeur R; Rogers KA; Bhat S; Jaglowski SM; Lockman H; Lapalombella R; Byrd JC; Woyach JA
Clin Cancer Res; 2022 Aug; 28(15):3242-3247. PubMed ID: 35608822
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
14. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
15. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Akpinar S; Dogu MH; Celik S; Ekinci O; Hindilerden IY; Dal MS; Davulcu EA; Tekinalp A; Hindilerden F; Ozcan BG; Hacibekiroglu T; Erkurt MA; Bagci M; Namdaroglu S; Korkmaz G; Bilgir O; Cagliyan GA; Ozturk HBA; Serin I; Tiryaki TO; Ozatli D; Korkmaz S; Ulas T; Eser B; Turgut B; Altuntas F
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):169-173. PubMed ID: 34629286
[TBL] [Abstract][Full Text] [Related]
16. FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL.
Dartigeas C; Slama B; Doyle M; Tapprich C; Albrecht C; Dupuis S; Wapenaar R; Schmidt-Hieber C; Leblond V
Clin Hematol Int; 2022 Sep; 4(3):65-74. PubMed ID: 36103041
[TBL] [Abstract][Full Text] [Related]
17. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
18. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
19. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
Tucker DL; Rule SA
Ther Clin Risk Manag; 2015; 11():979-90. PubMed ID: 26150724
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
